Yahoo India Web Search

Search results

  1. Sep 19, 2024 · Below are the latest The Lancet Respiratory Medicine articles published online ahead of issue publication. Many research papers have been peer-reviewed and published via a fast-track process within 10 weeks of submission. Current Issue. Online First.

  2. Sep 13, 2024 · "With over 80 years of experience in global cold chain transportation, Thermo King always adheres to the principles of customer focus, innovation and excellence," said Michael Shi, Thermo King Product Management and Engineering Leader, Asia Pacific.

  3. 2 days ago · HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments.

  4. Sep 20, 2024 · Michael Shi. www.trendzon1865.com. Trendzon Holdings Group Limited, an investment holding company, provides infrastructural pipeline construction and related engineering services for gas, water, telecommunications, and power industries in Singapore and the People’s Republic of China.

    • HK$4.05
    • 0.55
    • HK$0.17
    • HK$0.19
  5. 3 days ago · In this episode of We Got Your Mac, Victoria gets an update from Tom Rice on his ongoing Apple device deployment project. They discuss the challenges and solutions related to shared mobile devices, security, and compliance. Then, Victoria and Michael are joined by SHI’s AI PC expert Ruva Chimusoro, exploring what makes AI PCs unique, what their benefits are, and how organizations should approach them. This episode is sponsored by OtterBusiness. For more than 25 years, innovations from ...

  6. Sep 7, 2024 · A well-developed recommendation system can not only leverage multi-typed interactions (such as page view, add-to-cart, and purchase) to better identify user preferences, but also demonstrate high p...

  7. People also ask

  8. Sep 20, 2024 · Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20. Nov. 24. MT. Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating. Nov. 10. MT. Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating. 22-08-09.